In a report released yesterday, Liana Moussatos from Wedbush reiterated a Buy rating on Allena Pharmaceuticals (ALNA), with a price target of $26.00. The company’s shares closed last Monday at $1.87, close to its 52-week low of $1.55.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -10.6% and a 32.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
Currently, the analyst consensus on Allena Pharmaceuticals is a Strong Buy with an average price target of $14.67, which is a 794.0% upside from current levels. In a report issued on November 7, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.66 and a one-year low of $1.55. Currently, Allena Pharmaceuticals has an average volume of 312.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders.